Fowler Partners With Life Sciences Company to Create Experiential Learning Scenarios

Open the image full screen.

San Diego State University’s Fowler College of Business and Lõkahi Therapeutics recently announced a collaboration that will offer Fowler students experiential-learning engagement through Lõkahi’s ai² Future Lab™ to further enhance their career-readiness.

Beginning in the fall of 2026, four Fowler MBA students will work with the management team at Lõkahi Therapeutics, a La Jolla, California-based life sciences company, to help identify and evaluate promising therapeutic technologies that may have been initially overlooked and are no longer in active development. Technologies demonstrating potentially commercial or clinical viability may be considered by Lõkahi for future partnership or licensing opportunities.

The engagement is part of Fowler’s MBA strategic business consulting program, which gives graduate students opportunities to apply their classroom knowledge to real-world business challenges facing external organizations. Working as a consulting team, the students will conduct research, evaluate opportunities, and present strategic recommendations to Lõkahi’s management. 

“The pharmaceutical industry contains a significant number of promising therapeutic programs that have been abandoned for reasons unrelated to the underlying science,” said Brian Peters, Lõkahi’s senior vice president, ai² Division. “Through this partnership, SDSU students have the opportunity to help us identify, research and evaluate potential licensing candidates that provide a foundation for future business development activities.”

Student team member Aimee Keith said the project will allow the team to draw on their coursework while advancing an outcome with real-world potential. 

“Our team looks forward to using what we’ve learned in the classroom to help build a case for pursuing a biotech asset that was previously withdrawn from the research and development process,” she said. “We hope that our efforts shine a spotlight on a drug asset that can bring meaningful healing to communities nationwide.”